Literature DB >> 11033427

Cell cultures as tools in biopharmacy.

A Braun1, S Hämmerle, K Suda, B Rothen-Rutishauser, M Günthert, S D Krämer, H Wunderli-Allenspach.   

Abstract

A survey is given on a few selected cell culture models that are used for transport studies. They are characterised for growth, transcellular electrical resistance and cytoarchitecture. The importance of standardisation in view of their use as transport models is documented. Their potential for studies on passive permeation and P-glycoprotein-mediated transport is explored and related to published data. Transport studies are presented that were performed in a two-chamber set-up, the Costar "vertical diffusion system". A series of non-homologous compounds showed similar permeability data (P(app)) in the different cell cultures. The origin of the cell type had no remarkable influence on passive transcellular permeation. MDCK cells, an epithelial cell line of canine kidney origin, are perfectly suited to screen for passive permeation. They have low expression of transporter proteins and low metabolic activity. In general, they probably represent the best-known epithelial cell line with respect to genetics as well as lipid and protein composition. MDCK cells are easy to handle. Transport experiments can be done between 7 and 14 days after seeding, when the stationary growth phase is reached. To screen for P-glycoprotein substrates, efflux and uptake studies were performed with mdr1-transfected MDCK cells (MDR1-MDCK) in a one-chamber system in the presence or absence of verapamil or cyclosporin A as inhibitor. Evidence is presented why the transfected cells, which express large amounts of P-glycoprotein, are not suitable for two-chamber transport studies.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11033427     DOI: 10.1016/s0928-0987(00)00164-0

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  22 in total

1.  Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture.

Authors:  Elke Störmer; Lisa L von Moltke; Michael D Perloff; David J Greenblatt
Journal:  Pharm Res       Date:  2002-07       Impact factor: 4.200

Review 2.  Application of method suitability for drug permeability classification.

Authors:  Donna A Volpe
Journal:  AAPS J       Date:  2010-09-02       Impact factor: 4.009

Review 3.  Current industrial practices of assessing permeability and P-glycoprotein interaction.

Authors:  Praveen V Balimane; Yong-Hae Han; Saeho Chong
Journal:  AAPS J       Date:  2006-01-13       Impact factor: 4.009

4.  Multi-functional scaling methodology for translational pharmacokinetic and pharmacodynamic applications using integrated microphysiological systems (MPS).

Authors:  Christian Maass; Cynthia L Stokes; Linda G Griffith; Murat Cirit
Journal:  Integr Biol (Camb)       Date:  2017-04-18       Impact factor: 2.192

5.  Why we should be vigilant: drug cytotoxicity observed with in vitro transporter inhibition studies.

Authors:  Xiaowan Zheng; Lei Diao; Sean Ekins; James E Polli
Journal:  Biochem Pharmacol       Date:  2010-06-23       Impact factor: 5.858

6.  Development of an in vitro rat intestine segmental perfusion model to investigate permeability and predict oral fraction absorbed.

Authors:  Marc-Etienne Castella; Marianne Reist; Joachim M Mayer; Jean-Jacques Turban; Bernard Testa; Claire Boursier-Neyret; Bernard Walther; Jean-Marie Delbos; Pierre-Alain Carrupt
Journal:  Pharm Res       Date:  2006-06-21       Impact factor: 4.200

7.  Differential effect of P-gp and MRP2 on cellular translocation of gemifloxacin.

Authors:  Ramya Krishna Vadlapatla; Aswani Dutt Vadlapudi; Deep Kwatra; Dhananjay Pal; Ashim K Mitra
Journal:  Int J Pharm       Date:  2011-08-16       Impact factor: 5.875

8.  Cells on pores: a simulation-driven analysis of transcellular small molecule transport.

Authors:  Xinyuan Zhang; Nan Zheng; Peng Zou; Huaning Zhu; Juan P Hinestroza; Gus R Rosania
Journal:  Mol Pharm       Date:  2010-04-05       Impact factor: 4.939

9.  Substrate-dependent breast cancer resistance protein (Bcrp1/Abcg2)-mediated interactions: consideration of multiple binding sites in in vitro assay design.

Authors:  Nagdeep Giri; Sagar Agarwal; Naveed Shaik; Guoyu Pan; Ying Chen; William F Elmquist
Journal:  Drug Metab Dispos       Date:  2008-12-04       Impact factor: 3.922

10.  A modified coumarinic acid-based cyclic prodrug of an opioid peptide: its enzymatic and chemical stability and cell permeation characteristics.

Authors:  Hui Ouyang; Fuxing Tang; Teruna J Siahaan; Ronald T Borchardt
Journal:  Pharm Res       Date:  2002-06       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.